Core Insights - In 2025, the company achieved a revenue exceeding 50 billion yuan for the first time, with a net profit growth of over 30.9% year-on-year, marking a significant recovery from the brand crisis faced in 2024 [2][3] - The company's strategy focuses on product quality and consumer trust, emphasizing the differentiation of its bottled water through a commitment to natural sources rather than industrial standards [3][5] Group 1: Bottled Water Business - The bottled water segment saw a recovery in 2025, driven by a shift in consumer perception rather than price wars or channel subsidies [3] - The company has increased the visibility of its water sources through various marketing strategies, including labeling and public tours, to counteract emotional skepticism [3][4] - The long-term strategy involves significant investment in water source infrastructure, with 16 water sources established nationwide, creating a resource-based competitive advantage [4] Group 2: Tea Beverage Segment - The core brand, Dongfang Shuye, dominated the sugar-free tea market in 2025, benefiting from the rapid growth of this beverage category [6] - The company has successfully positioned itself in the ready-to-drink Longjing tea market, leveraging its industrial capabilities and long-term investments in tea sourcing [8][9] - The company adopts a restrained approach by limiting the production of Longjing tea to specific seasons, ensuring quality and maintaining brand integrity [9] Group 3: Product-Centric Strategy - The company is recognized as a "consumer white horse stock," but operates more like a product-focused company, emphasizing quality over rapid market entry [10] - Its product matrix, including natural water and various tea products, has shown resilience across market cycles, providing stability against external shocks [11] - The recovery in 2025 is seen as a validation of the company's long-term commitment to product quality and operational excellence, rather than a mere reaction to market fluctuations [11]

（原标题：昆仑能源(00135)将于7月21日派发末期股息每股0.1498元） 智通财经APP讯，昆仑能源(00135)发布公告，该公司将于2026年7月21日派发截至2025年12月31日止的 末期股息每股0.1498元。 ...

智通财经APP讯，昆仑能源(00135)公布，独立非执行董事辛定华先生，即公司审核委员会主席、薪酬委 员会及提名委员会的成员，已获委任为首席独立非执行董事，自2026年3月24日起生效。 （原标题：昆仑能源(00135)委任辛定华为首席独立非执行董事） ...

（原标题：昆仑能源(00135)公布2025年业绩 股东应占溢利53.46亿元 同比减少10.3%） 智通财经APP讯，昆仑能源(00135)公布2025年业绩，收入1939.79亿元，同比增长3.71%;公司股东应占 溢利53.46亿元，同比减少10.3%;每股基本盈利61.74分，拟派付末期股息每股16.84港仙。 公告称，收入增加主要由于工业用户与分销与贸易业务增长带动销售量增加，使天然气销售板块收入增 加。 天然气销售业务：深耕市场、优化结构，核心业务顶压前行。坚持存量市场挖潜与增量市场合作开发并 重，依托覆盖全国的客户规模和网络站点，在内蒙古、山东、贵州、江苏等8个省市新开发城燃项目11 个，新增年销售能力7.8亿立方米，客户规模增长到1,719万户。持续推进终端价格顺导，居民用气顺价 率69%，同比提高8.3个百分点。不断优化销售结构，工业气量保持较快增长，占零售气量比重77.7%， 同比提升2.8个百分点。天然气总销量592.6亿立方米、同比增长9.4%，其中零售气量达到335.1亿立方 米。 LNG加工与储运业务：延伸产业链、提升价值链，逐步成长为第二利润增长极。LNG销售取得里程碑 式跨越， ...

Core Viewpoint - The launch of Pemafibrate (brand name: Pailongda®) by Xinghe Co., Ltd. on Alibaba Health marks the first official online availability of this next-generation selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) [1][4]. Group 1: Product Launch and Market Entry - Pemafibrate has been approved by the National Medical Products Administration since April 2025 and is now available through an authorized e-commerce platform, ensuring patients can purchase it with confidence [1]. - The drug has been on the market in Japan for nine years and is recognized as an original research drug for lowering triglycerides [4]. Group 2: Clinical Efficacy and Advantages - Pemafibrate demonstrates significant clinical advantages over traditional lipid-lowering medications, with a unique "Y-shaped" molecular structure that activates PPARα with over 2500 times the potency of conventional fibrates [3]. - In clinical trials, a daily dose of 0.4 mg resulted in a triglyceride reduction of 51.8%, outperforming fenofibrate, and effectively increasing high-density lipoprotein cholesterol while lowering atherogenic remnant lipoprotein cholesterol [3]. Group 3: Target Patient Population - The drug is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and can be used alone or in combination with statins [3][4]. - Pemafibrate has received recognition from various authoritative guidelines, including the "Chinese Lipid Management Guidelines (2023)" and others, validating its efficacy and usage standards [4].

Core Viewpoint - The launch of PemaBet® (派龙达®), a new generation selective PPARα modulator, on Alibaba Health marks its first availability to patients nationwide since receiving approval from the National Medical Products Administration in April 2025 [1] Company Summary - Xinghe Pharmaceutical's PemaBet® is now accessible through an official e-commerce platform, expanding its reach to patients across China [1]

| 渣打集团 | | | | | --- | --- | --- | --- | | 分时图 | 日K线 | 周K线 | 月K线 | 渣打集团(02888)发布公告，于2026年3月20日，该公司斥资1509.28万英镑回购98.56万股。 ...

Company News - Li Auto announced a $1 billion stock repurchase plan [1] - Tesla updated the delivery expectation for all Model 3 variants to 3-5 weeks [1] Market Dynamics - Major U.S. stock index futures showed weakness before the market opened, with Dow futures down 0.3%, S&P 500 futures down 0.29%, and Nasdaq futures down 0.3% [1] - Most major European stock indices declined, with the FTSE 100 down 0.08% and the DAX down 0.35% [1] - Popular Chinese concept stocks showed mixed performance before the market opened, with Li Auto rising over 3% and Bilibili falling over 2% [1]

Core Viewpoint - The company reported a revenue of approximately 22.07 billion yuan for the fiscal year 2025, reflecting a year-on-year increase of 2.7% [1] Financial Performance - Gross margin slightly decreased to 37.1%, primarily due to an increase in the sales proportion of lower-margin water products and sustained high aluminum prices, which raised the procurement costs of raw materials for cans [1] - Adjusted EBIT reached 1.979 billion yuan, representing a year-on-year growth of 6.1% [1] - Adjusted EBITDA was 2.872 billion yuan, showing a year-on-year increase of 5.5% [1] Product Performance - The core Coca-Cola product line experienced a recovery in sales, with revenue growth surpassing the same period last year [1] - The smart retail business and COFCO Yueshanghui also achieved steady revenue growth [1] - The non-Coca-Cola product business continued to expand, becoming a significant driver of the company's performance growth [1]

北京商报讯（记者 孔文燮）3月24日，农夫山泉披露的2025年报显示，报告期内实现营收约为525.53亿 元，同比增长22.51%；实现归母净利润约为158.68亿元，同比增长30.89%。其中，茶饮料板块营收增长 近29%，达到215.96亿元；功能饮料与果汁饮料分别录得16.8%与26.7%的双位数高增长。农夫山泉创始 人钟睒睒在业绩公告中表示，"2025年公司饮用水业务已恢复增长，比2024年同期增长17.3%。目前， 农夫山泉继续稳居中国包装饮用水市场占有率第一的位置"。据了解，2025年，农夫山泉新增湖南八大 公山、四川龙门山、西藏念青唐古拉山三个水源地，2026年又再新增云南轿子雪山水源地。目前，农夫 山泉已在全国布局16个优质水源地。 ...